Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate.

Slides:

Advertisements

Similar presentations

Early Detection of Prostate Cancer in 2007

Advertisements

Volume 55, Issue 1, Pages 1-8 (January 2009)

The PSA Era is not Over for Prostate Cancer

Volume 71, Issue 6, Pages (June 2017)

Volume 69, Issue 3, Pages (March 2016)

Volume 72, Issue 2, Pages (August 2017)

Volume 64, Issue 6, Pages (December 2013)

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 52, Issue 3, Pages (September 2007)

Volume 59, Issue 1, Pages (January 2011)

Volume 56, Issue 6, Pages (December 2009)

Volume 60, Issue 1, Pages (July 2011)

Volume 63, Issue 1, Pages (January 2013)

Volume 67, Issue 3, Pages (March 2015)

European Urology Oncology

Volume 64, Issue 6, Pages (December 2013)

Volume 61, Issue 2, Pages (February 2012)

Prostate Cancer Epidemic in Sight?

Volume 66, Issue 1, Pages (July 2014)

Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer Sam Ladjevardi, Gabriel Sandblom,

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 54, Issue 4, Pages (October 2008)

Volume 52, Issue 3, Pages (September 2007)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 69, Issue 3, Pages (March 2016)

European Urology Oncology

Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal.

Prostate Cancer Detection: A View of the Future

Volume 56, Issue 2, Pages (August 2009)

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 69, Issue 6, Pages (June 2016)

Volume 67, Issue 4, Pages (April 2015)

Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions Anwar R. Padhani, Jeffrey Weinreb, Andrew.

Volume 66, Issue 6, Pages (December 2014)

Prostate Cancer Epidemic in Sight?

The PSA Era is not Over for Prostate Cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Volume 66, Issue 2, Pages (August 2014)

Tillmann Loch, Pat Fox Fulgham European Urology

Volume 68, Issue 4, Pages (October 2015)

Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer Valeria.

Volume 67, Issue 6, Pages (June 2015)

Volume 65, Issue 4, Pages (April 2014)

Volume 68, Issue 6, Pages (December 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 66, Issue 3, Pages (September 2014)

Volume 64, Issue 4, Pages (October 2013)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

European Urology Oncology

European Urology Oncology

Volume 53, Issue 1, Pages (January 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 75, Issue 4, Pages (April 2019)

Volume 59, Issue 4, Pages (April 2011)

Volume 73, Issue 1, Pages (January 2018)

The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance.

Volume 65, Issue 3, Pages (March 2014)

Volume 75, Issue 4, Pages (April 2019)

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

Volume 69, Issue 1, Pages (January 2016)

Not All Multiparametric Magnetic Resonance Imaging–targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection.

Volume 51, Issue 2, Pages (February 2007)

Volume 54, Issue 3, Pages (September 2008)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

European Urology Oncology

European Urology Oncology

European Urology Oncology

Presentation transcript:

Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer Wulphert Venderink, Annemarijke van Luijtelaar, Joyce G.R. Bomers, Marloes van der Leest, Christina Hulsbergen-van de Kaa, Jelle O. Barentsz, J.P. Michiel Sedelaar, Jurgen J. Fütterer European Urology DOI: 10.1016/j.eururo.2017.02.021 Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 1 Patient flow chart. MRGB=magnetic resonance imaging guided prostate biopsy; PI-RADS=Prostate Imaging Reporting and Data System; PCa=prostate cancer; GS=Gleason score. European Urology DOI: (10.1016/j.eururo.2017.02.021) Copyright © 2017 European Association of Urology Terms and Conditions

Fig. 2 Detection rates differentiated per location. Clinically significant prostate cancer (csPCa) detection rates (%, n) are displayed based on the location of the lesion detected on multiparametric magnetic resonance imaging. For example, the csPCa detection rate for lesions covering both the mid and the apex region of the prostate is 57% (83/145). In Table 7, csPCa detection rates per subcohort are displayed. European Urology DOI: (10.1016/j.eururo.2017.02.021) Copyright © 2017 European Association of Urology Terms and Conditions